Neuphoria Therapeutics Inc. (NEUP)
Nasdaq · Healthcare · Biotechnology
$3.45−0.58%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $18.7M
- 52-week range
- $3.19 – $21.40
- 52-week change
- −81.51%
- EPS (trailing)
- −$3.06
Fiscal year to Jun 2026
- Revenue
- $1.2M (−92.50%)
- Net income
- −$13.5M
- Operating margin
- −1401.0%
- Diluted EPS
- −$3.06
From the company’s annual report on SEC EDGAR.
About Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.
Headquarters: Millis, United States · 1 employees · neuphoriatx.com